TP53 and cancer: Small-molecule inhibitors of MDM2 blocking MDM2-p53 interaction or inhibiting ubiquitin ligase activity of MDM2 have been actively studied in advanced preclinical development or early-phase clinical trials for the treatment of cancer 2, 22, 23, 27, 28.